クロストリジウム・ディフィシル腸炎
(偽膜性大腸炎 から転送)
出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2024/02/25 13:38 UTC 版)
クロストリジウム・ディフィシル腸炎(クロストリジウム・ディフィシルちょうえん、英語: Clostridium difficile colitis)(CD腸炎)または偽膜性大腸炎(ぎまくせいだいちょうえん、英語: Pseudomembranous colitis)は、芽胞産生性偏性嫌気性細菌であるクロストリディオイデス・ディフィシル(Clostridioides difficile)の異常増殖の結果として生じる大腸炎である[1][2]。クロストリジウム・ディフィシル関連下痢症 (C. difficile associated diarrhea, CDAD) と呼ばれる炎症性下痢症の原因となる[3]。潜在性のC. difficile 感染症 (CDI) は、しばしばインフルエンザ様症状と共通点があり、炎症性腸疾患患者の場合には腸炎の再燃を思わせる[4]。C. difficile が産生する毒素は腹痛を伴う巨大結腸症(中毒性巨大結腸症)や下痢を引き起こし、重篤となる場合もある[3]。
- ^ a b “Clostridium difficile: A Cause of Diarrhea in Children”. JAMA Pediatrics 167 (6): 592. (June 2013). doi:10.1001/jamapediatrics.2013.2551. PMID 23733223 .
- ^ 岡健太郎、高橋志達、神谷茂、Clostridium difficile腸炎とプロバイオティクス 腸内細菌学雑誌 Vol.29 (2015) No.4 p.177-185, doi:10.11209/jim.29.177
- ^ a b c d 鈴木康夫、抗生物質起因性腸炎の診療 日本消化器病学会雑誌 107巻 (2010) 12号 p.1897-1904, doi:10.11405/nisshoshi.107.1897
- ^ Binion, David G (2010). “Clostridium difficile and IBD”. Inflammatory Bowel Disease Monitor 11 (1): 7–14 .
- ^ a b Lawson, Paul A.; Citron, Diane M.; Tyrrell, Kerin L.; Finegold, Sydney M. (2016-8). “Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938”. Anaerobe 40: 95–99. doi:10.1016/j.anaerobe.2016.06.008. ISSN 1095-8274. PMID 27370902 .
- ^ 話題の感染症 ディフィシル菌感染症の基礎と臨床 モダンメディア 2010年10月号(第56巻10号) (PDF)
- ^ Curry J (2007年7月20日). “Pseudomembranous Colitis”. WebMD. 2008年11月17日閲覧。
- ^ a b c d e f g h Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 322–4. ISBN 0-8385-8529-9
- ^ a b Lessa, Fernanda C.; Mu, Yi; Bamberg, Wendy M.; Beldavs, Zintars G.; Dumyati, Ghinwa K.; Dunn, John R.; Farley, Monica M.; Holzbauer, Stacy M. et al. (26 February 2015). “Burden of Infection in the United States”. New England Journal of Medicine 372 (9): 825–834. doi:10.1056/NEJMoa1408913.
- ^ Liddell-Scott. “κλωστήρ”. Greek-English Lexicon (Oxford){{inconsistent citations}}
- ^ Cawley, Kevin. “Difficilis”. Latin Dictionary and Grammar Aid (University of Notre Dame) 2013年3月16日閲覧。{{inconsistent citations}}
- ^ 國島広之「Clostridium difficile」『臨床検査』第58巻第7号、2008年7月15日、722-3頁、doi:10.11477/mf.1542101657、ISSN 0485-1420、2016年7月7日閲覧。
- ^ a b c d e 岡健太郎、高橋志達、神谷茂、Clostridium difficile腸炎とプロバイオティクス 腸内細菌学雑誌 29巻 (2015) 4号 p.177-185, doi:10.11209/jim.29.177
- ^ “Inpatient diarrhoea and Clostridium difficile infection”. Clinical Medicine 12 (6): 583–588. (2012). doi:10.7861/clinmedicine.12-6-583.
- ^ Bomers, Marije (April 2015). “Rapid, Accurate, and On-Site Detection of C. difficile in Stool Samples”. The American Journal of Gastroenterology 110 (4): 588–594. doi:10.1038/ajg.2015.90. PMID 25823766.
- ^ “Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea”. The American Journal of Medicine 100 (5): 487–95. (May 1996). doi:10.1016/S0002-9343(95)00016-X. PMID 8644759.
- ^ Di Bella, Stefano; Ascenzi, Paolo; Siarakas, Steven; Petrosillo, Nicola; di Masi, Alessandra (2016-01-01). “Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects”. Toxins 8 (5). doi:10.3390/toxins8050134. ISSN 2072-6651. PMC 4885049. PMID 27153087 .
- ^ “The low molecular mass GTP-binding protein Rh is affected by toxin a from Clostridium difficile”. The Journal of Clinical Investigation 95 (3): 1026–31. (1995). doi:10.1172/JCI117747. PMC 441436. PMID 7883950 .
- ^ “Binary Bacterial Toxins: Biochemistry, Biology, and Applications of Common Clostridium and Bacillus Proteins”. Microbiology and Molecular Biology Reviews : MMBR 68 (3): 373–402, table of contents. (2004). doi:10.1128/MMBR.68.3.373-402.2004. PMC 515256. PMID 15353562 .
- ^ “A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality”. The New England Journal of Medicine 353 (23): 2442–9. (December 2005). doi:10.1056/NEJMoa051639. PMID 16322602.
- ^ McDonald LC (August 2005). “Clostridium difficile: responding to a new threat from an old enemy”. Infection Control and Hospital Epidemiology 26 (8): 672–5. doi:10.1086/502600. PMID 16156321 .
- ^ 山根誠久、仲宗根勇、「グラム陰性球菌、グラム陽性桿菌 病院感染を起こす代表的な微生物(感染経路と病原性)」 『環境感染』 2000年 15巻 Supplement号 p.33-36, doi:10.11550/jsei1986.15.Supplement_33
- ^ “Clostridium difficile infection: New developments in epidemiology and pathogenesis”. Nature Reviews. Microbiology 7 (7): 526–36. (July 2009). doi:10.1038/nrmicro2164. PMID 19528959.
- ^ Luciano, JA; Zuckerbraun, BS (December 2014). “Clostridium difficile infection: prevention, treatment, and surgical management”. The Surgical clinics of North America 94 (6): 1335–49. doi:10.1016/j.suc.2014.08.006. PMID 25440127.
- ^ “Scientists probe whether C. difficile is linked to eating meat”. CBC News. (2006年10月4日). オリジナルの2006年10月24日時点におけるアーカイブ。
- ^ “Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection”. The Journal of Infectious Diseases 166 (3): 561–7. (September 1992). doi:10.1093/infdis/166.3.561. PMID 1323621.
- ^ Halsey J (2008). “Current and future treatment modalities for Clostridium difficile-associated disease”. American Journal of Health-System Pharmacy 65 (8): 705–15. doi:10.2146/ajhp070077. PMID 18387898.
- ^ “Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection”. Archives of Internal Medicine 170 (9): 784–90. (May 2010). doi:10.1001/archinternmed.2010.89. PMID 20458086.
- ^ “Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis”. Clinical Gastroenterology and Hepatology 10 (3): 225–33. (March 2012). doi:10.1016/j.cgh.2011.09.030. PMID 22019794.
- ^ Sarah A. Kuehne; Stephen T. Cartman; John T. Heap; Michelle L. Kelly; Alan Cockayne; Nigel P. Minton (2010). “The role of toxin A and toxin B in Clostridium difficile infection”. Nature 467 (7316): 711–3. doi:10.1038/nature09397. PMID 20844489.
- ^ “Surgical Pathology Criteria: Pseudomembranous Colitis”. Stanford School of Medicine. 2016年7月7日閲覧。
- ^ Manual of Clinical Microbiology (8th ed.). Washington DC: ASM Press. (2003). ISBN 1-55581-255-4[要ページ番号]
- ^ “Repeat Stool Testing to Diagnose Clostridium difficile Infection Using Enzyme Immunoassay Does Not Increase Diagnostic Yield”. Clinical Gastroenterology and Hepatology 9 (8): 665–669.e1. (2011). doi:10.1016/j.cgh.2011.04.030. PMID 21635969.
- ^ Anna Salleh (2009年3月2日). “Researchers knock down gastro bug myths”. ABC Science Online. 2009年3月2日閲覧。
- ^ “Toxin B is essential for virulence of Clostridium difficile”. Nature 458 (7242): 1176–9. (2009). doi:10.1038/nature07822. PMC 2679968. PMID 19252482 .
- ^ “Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile Infection: a meta-analysis.”. Clinical Infectious Diseases 53 (7): e81–90. (October 2011). doi:10.1093/cid/cir505. PMID 21890762.
- ^ Weiss AJ, Elixhauser A. Origin of Adverse Drug Events in U.S. Hospitals, 2011. HCUP Statistical Brief #158. Agency for Healthcare Research and Quality, Rockville, MD. July 2013. [1]
- ^ a b “Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?”. Current Gastroenterology Reports 14 (4): 343–8. (August 2012). doi:10.1007/s11894-012-0274-4. PMID 22763792 .
- ^ a b “Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis.”. Annals of Internal Medicine 157 (12): 878–88. (18 December 2012). doi:10.7326/0003-4819-157-12-201212180-00563. PMID 23362517.
- ^ a b c d e “Probiotics in Clostridium difficile Infection”. Journal of Clinical Gastroenterology 45 (Suppl): S154–8. (November 2011). doi:10.1097/MCG.0b013e31822ec787. PMID 21992956.
- ^ McFarland LV (April 2006). “Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease”. The American Journal of Gastroenterology 101 (4): 812–22. doi:10.1111/j.1572-0241.2006.00465.x. PMID 16635227.
- ^ “Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.”. The Cochrane Database of Systematic Reviews 5: CD006095. (31 May 2013). doi:10.1002/14651858.CD006095.pub3. PMID 23728658.
- ^ Mayo Clinic C. diff prevention
- ^ a b “Strategies to Prevent Clostridium difficile Infections in Acute Care Hospitals: 2014 Update.”. Infection Control and Hospital Epidemiology 35 (6): 628–45. (Jun 2014). doi:10.1086/676023. PMID 24799639.
- ^ Roehr B (2007年9月21日). “Alcohol Rub, Antiseptic Wipes Inferior at Removing Clostridium difficile”. Medscape. 2016年7月7日閲覧。
- ^ “Host S-nitrosylation inhibits clostridial small molecule–activated glucosylating toxins”. Nature Medicine 17 (9): 1136–41. (2011). doi:10.1038/nm.2405. PMC 3277400. PMID 21857653 . 非専門家向けの内容要旨 – ScienceDaily (21 August 2011).
- ^ Laidman J (2011年12月29日). “Flush With Germs: Lidless Toilets Spread C. difficile”. Medscape. 2016年7月7日閲覧。
- ^ “Cleaning agents 'make bug strong'”. BBC News Online. (2006年4月3日) 2008年11月17日閲覧。
- ^ Boyce et al. 2008
- ^ Manian et al. 2010
- ^ “Performance Feedback, Ultraviolet Cleaning Device, and Dedicated Housekeeping Team Significantly Improve Room Cleaning, Reduce Potential for Spread of Common, Dangerous Infection”. Agency for Healthcare Research and Quality (2014年1月15日). 2014年1月20日閲覧。
- ^ a b “Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.”. The Cochrane Database of Systematic Reviews (9): CD004610. (7 September 2011). doi:10.1002/14651858.CD004610.pub4. PMID 21901692.
- ^ a b “Comparative effectiveness of Clostridium difficile treatments: a systematic review”. Annals of Internal Medicine 155 (12): 839–47. (20 December 2011). doi:10.7326/0003-4819-155-12-201112200-00007. PMID 22184691.
- ^ a b c d Surawicz, Christina M; Brandt, Lawrence J; Binion, David G; Ananthakrishnan, Ashwin N; Curry, Scott R; Gilligan, Peter H; McFarland, Lynne V; Mellow, Mark et al. (26 February 2013). “Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections”. The American Journal of Gastroenterology 108 (4): 478–498. doi:10.1038/ajg.2013.4. PMID 23439232.
- ^ a b “Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.”. American Journal of Health-System Pharmacy 69 (11): 933–43. (1 June 2012). doi:10.2146/ajhp110371. PMID 22610025.
- ^ Cornely OA (December 2012). “Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?”. Clinical Microbiology and Infection 18 Suppl 6: 28–35. doi:10.1111/1469-0691.12012. PMID 23121552.
- ^ Cunha, Burke A. (2013). Antibiotic Essentials 2013 (12 ed.). p. 133. ISBN 978-1-284-03678-7
- ^ a b Stroehlein JR (2004). “Treatment of Clostridium difficile Infection”. Current Treatment Options in Gastroenterology 7 (3): 235–9. doi:10.1007/s11938-004-0044-y. PMID 15149585.
- ^ a b “MSD、クロストリジウム・ディフィシル感染症の再発抑制薬「ジーンプラバ 点滴静注625mg」を発売”. (2017年12月8日) (2017/12/8発行)
- ^ “Clostridium difficile: controversies and approaches to management”. Current Opinion in Infectious Diseases 22 (6): 517–24. (December 2009). doi:10.1097/QCO.0b013e32833229ce. PMID 19738464.
- ^ Pillai A, Nelson R (23 January 2008). Pillai, Anjana. ed. “Probiotics for treatment of Clostridium difficile-associated colitis in adults”. The Cochrane Database of Systematic Reviews (1): CD004611. doi:10.1002/14651858.CD004611.pub2. PMID 18254055.
- ^ Woo, TD; Oka, K; Takahashi, M; Hojo, F; Osaki, T; Hanawa, T; Kurata, S; Yonezawa, H et al. (November 2011). “Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain”. Journal of Medical Microbiology 60 (11): 1617–25. doi:10.1099/jmm.0.033423-0. PMID 21700738.
- ^ “Fecal Transplantation for Recurrent Clostridium difficile Infection in Older Adults: A Review.”. Journal of the American Geriatrics Society 61 (8): 1394–8. (August 2013). doi:10.1111/jgs.12378. PMID 23869970.
- ^ a b Drekonja, D; Reich, J; Gezahegn, S; Greer, N; Shaukat, A; MacDonald, R; Rutks, I; Wilt, TJ (5 May 2015). “Fecal Microbiota Transplantation for Clostridium difficile Infection: A Systematic Review”. Annals of Internal Medicine 162 (9): 630–8. doi:10.7326/m14-2693. PMID 25938992.
- ^ “Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile”. The New England Journal of Medicine 368 (5): 407–15. (January 2013). doi:10.1056/NEJMoa1205037. PMID 23323867.
- ^ Jop De Vrieze (30 August 2011). “The Promise of Poop”. Science 341: 954–957. doi:10.1126/science.341.6149.954.
- ^ Keller, JJ; Kuijper, EJ (2015). “Treatment of recurrent and severe Clostridium difficile infection”. Annual Review of Medicine 66: 373–86. doi:10.1146/annurev-med-070813-114317. PMID 25587656.
- ^ Smith, Peter Andrey (2015年11月10日). “Fecal Transplants Made (Somewhat) More Palatable”. The New York Times: p. D5 2015年11月13日閲覧。
- ^ “Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis”. The British Journal of Surgery 99 (11): 1501–13. (November 2012). doi:10.1002/bjs.8868. PMID 22972525.
- ^ “Emergency colectomy for fulminant Clostridium difficile colitis: Striking the right balance”. Scandinavian Journal of Gastroenterology 46 (10): 1222–7. (October 2011). doi:10.3109/00365521.2011.605469. PMID 21843039.
- ^ a b “Clostridium difficile—more difficult than ever”. The New England Journal of Medicine 359 (18): 1932–40. (October 2008). doi:10.1056/NEJMra0707500. PMID 18971494.
- ^ a b others], editor-in-chief, Frank J. Domino ; associate editors, Robert A. Baldor (2014). The 5-minute clinical consult 2014 (22nd ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 258. ISBN 978-1-4511-8850-9
- ^ “Antibiotic resistance threats in the United States, 2013”. US Centers for Disease Control and Prevention (2013年). 2014年11月3日閲覧。
- ^ “Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis”. American Journal of Diseases of Children 49 (2): 390–402. (1935). doi:10.1001/archpedi.1935.01970020105010 .
- ^ “Clostridium difficile and the aetiology of pseudomembranous colitis”. Lancet 311 (8073): 1063–6. (May 1978). doi:10.1016/S0140-6736(78)90912-1. PMID 77366.
- ^ Campus, University of Massachusetts Worcester. “op-line data from randomized, double-blind, placebo controlled Phase 2 clinical trial indicate statistically significant reduction in recurrences of CDAD”. 2010年12月27日時点のオリジナルよりアーカイブ。2011年8月16日閲覧。
- ^ CenterWatch. “Clostridium Difficile-Associated Diarrhea”. 2011年8月16日閲覧。
- ^ Business, Highbeam. “MDX 066, MDX 1388 Medarex, University of Massachusetts Medical School clinical data (phase II)(diarrhea)”. 2011年8月16日閲覧。
- ^ a b c d e Shah D, Dang MD, Hasbun R, Koo HL, Jiang ZD, DuPont HL, Garey KW; Dang; Hasbun; Koo; Jiang; Dupont; Garey (May 2010). “Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance”. Expert Review of Anti-Infective Therapy 8 (5): 555–64. doi:10.1586/eri.10.28. PMC 3138198. PMID 20455684 .
- ^ Barlow, Andrew; Muhleman, Mitchel; Gielecki, Jerzy; Matusz, Petru; Tubbs, R. Shane; Loukas, Marios (2013). “The Vermiform Appendix: A Review”. Clinical Anatomy 26 (7): 833–842. doi:10.1002/ca.22269. PMID 23716128 .
- ^ Gerding, Dale N.; Meyer, Thomas; Lee, Christine; Cohen, Stuart H.; Murthy, Uma K.; Poirier, Andre; Van Schooneveld, Trevor C.; Pardi, Darrell S. et al. (5 May 2015). “Administration of Spores of Nontoxigenic Strain M3 for Prevention of Recurrent Infection”. JAMA 313 (17): 1719. doi:10.1001/jama.2015.3725.
偽膜性大腸炎と同じ種類の言葉
- 偽膜性大腸炎のページへのリンク